Results 61 to 70 of about 627,391 (362)

Growth Hormone (GH)-Releasing Peptide Stimulation of GH Release from Human Somatotroph Adenoma Cells: Interaction with GH-Releasing Hormone, Thyrotropin- Releasing Hormone, and Octreotide. [PDF]

, 1994
The synthetic hexapeptide GH-releasing peptide (GHRP; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) specifically stimulates GH secretion in humans in vivo and in animals in vitro and in vivo via a still unknown receptor and mechanism.
Brockmeier, S., Lange, M., Müller, Otto-Albrecht, Renner, U., Schopohl, Jochen, Stalla, G. K., Strasburger, Christian J., Werder, K. von   +7 more
core   +1 more source

Counterbalancing O‐GlcNAcylation and STAT3 Phosphorylation in Ventral Tegmental Area Dopaminergic Neurons Mediates Behavioral Adaptations to Acute Restraint Stress

Advanced Science, EarlyView.
Acute restraint stress enhances STAT3Ser727 phosphorylation in dopaminergic neurons in mice. This modification promotes the upregulation of GABBR2 and GABRB3, reduces neuronal activity, and contributes to anxiety‐like behavior and diminished reward‐seeking following stress exposure.
Mingshuo Shao, Yi Wu, Haiyang Wang, Chenchun Zhang, Ying Zhu, Yan Jiang, Changyou Jiang, Qiumin Le, Xing Liu, Lan Ma, Feifei Wang   +10 more
wiley   +1 more source

Corticosterone Contributes to Context‐Triggered Retrieval of Morphine Withdrawal Memories by Acting on Basolateral Amygdala Neurons Projecting to Nucleus Accumbens Core

Advanced Science, EarlyView.
Context associated with morphine withdrawal elicits an increase in serum corticosterone levels. Corticosterone participates in CTR‐MWM by acting on MR, but not GR, in the BLA. MR in BLA→NAcC neurons mediates CTR‐MWM. MR increases presynaptic glutamate release and meanwhile participates in D1 receptor‐induced increases in presynaptic glutamate release ...
Zixuan Cao, Yaxian Wen, Yuanqi Chen, Yali Fu, Hao Yang, Chenshan Chu, Xinli Guo, Yu Yuan, Chao Lei, Huan Sheng, Da Shao, Li Yang, Dongyang Cui, Ming Chen, Bin Lai, Ping Zheng   +15 more
wiley   +1 more source

The STUB1-TPIT axis regulates the secretion of adrenocorticotrophic hormone in cushing disease

Journal of Translational Medicine
Background Cushing’s disease (CD) is a clinical syndrome caused by excessive secretion of adrenocorticotropic hormone (ACTH) from a pituitary corticotroph adenoma, resulting in adrenal cortical hyperplasia and overproduction of cortisol.
Fang Liu, Yanting Liu, Tao Zhang, Ning Huang, Desheng Chen, Xiaobin Wang, Jiangong Ma, Li Xue, Shaojian Lin, Zhe Bao Wu   +9 more
doaj   +1 more source

Norepinephrine Induces Sertoli Cell Ferroptosis via Receptors Desensitization Causing Stress‐Related Male Reproductive Dysfunction

Advanced Science, EarlyView.
Psychological stress activates the sympathetic–adrenal axis, elevating norepinephrine (NE) and suppressing reproductive hormones, thereby impairing male reproduction. Excess NE overactivates and desensitizes β‐adrenergic receptors (β‐ARs), triggering Sertoli cell ferroptosis and disrupting spermatogenesis.
Lingyu Zhang, Shanfeng Gao, Xiaofan Xiong, Xin Liu, Rufeng Li, Xia Wang, Lin Han, Xuan Xiao, Xiaofei Wang, Wen Li, Yongxia Chang, Yuefeng Du, Juan Yang   +12 more
wiley   +1 more source

Cholesterol-activated stress granules reduce the membrane localization of DRD2 and promote prolactinoma dopamine agonists resistance

Acta Neuropathologica Communications
Prolactinoma is the most prevalent pituitary neuroendocrine tumor and dopamine agonists (DAs) targeting dopamine D2 receptor (DRD2) are recommended as the first-line treatment. However, varying degrees of DA resistance limit patient benefit.
Yuyang Peng, Huachun Yin, Xiangdong Pei, Yuan Zhang, Chengcheng Wang, Xin Zheng, Hong Liang, Hui Yang, Song Li   +8 more
doaj   +1 more source

Status of temozolomide use without insurance coverage in patients with aggressive pituitary neuroendocrine tumors

Endocrine Journal
The 2017 World Health Organization classification described aggressive pituitary neuroendocrine tumor (PitNET) as “a tumor with strong invasiveness and rapid growth, which is difficult to treat with surgery, radiation therapy, or drug therapy,” which ...
Atsushi Ishida, Naoko Inoshita, Noriaki Tanabe, Koji Takano, Hideki Shiramizu, Haruko Yoshimoto, Masataka Kato, Go Matsuoka, Shozo Yamada   +8 more
doaj   +1 more source

The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]

, 2016
Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea, Diaz, Graciela Susana, Recouvreux, Maria Victoria, Rifkin, Daniel B.   +3 more
core   +2 more sources

Cancer Neuroscience: Decoding Neural Circuitry in Tumor Evolution for Targeted Therapy

Advanced Science, EarlyView.
This review highlights the pivotal role of the nervous system in cancer progression, emphasizing how neural–tumor interactions—via synaptic signaling, neurotransmitters, and paracrine factors—reshape the tumor microenvironment. It introduces cancer neuroscience as an emerging field and proposes integrating advanced tools such as AI and optogenetics to ...
Mengyu Yuan, Rongjiao Xi, Yong Kang, Ming‐jie Kuang, Xiaoyuan Ji   +4 more
wiley   +1 more source

Pituitary apoplexy induced by gonadotropin-releasing hormone agonist administration: a rare complication of prostate cancer treatment

Endocrinology, Diabetes & Metabolism Case Reports, 2020
Gonadotropin-releasing hormone (GnRH) agonists, currently used in the treatment of advanced prostate cancer, have been described as a rare cause of pituitary apoplexy, a potentially life-threatening clinical condition. We report the case of a 69-year-old
Mariana Barbosa, Sílvia Paredes, Maria João Machado, Rui Almeida, Olinda Marques   +4 more
doaj   +1 more source